This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Tamir Biotechnology, Inc.
Drug Names(s): Ranpirnase
Description: ONCONASE (Ranpirnase) is a novel amphibian ribonuclease that belongs to the superfamily of pancreatic ribonuclease. It is a single peptide chain containing 104 amino acids. ONCONASE induces intracellular RNA degradation, triggering several biological effects simultaneously including the induction of the intrinsic (mitochondria) pathway of apoptosis and modulation of the expression of several key cell cycle regulatory factors.
Alfacell and GENESIS Pharma
In December 2006, Alfacell entered into a exclusive licensing and distribution agreement with GENESIS Pharma for the commercialization of Onconase. Under the agreement terms, Alfacell grants exclusive marketing and distribution rights for Onconase to GENESIS for UMM and any future oncology indications for the term of the agreement in eight countries in Southeast Europe, including Greece, Cyprus, Bulgaria, Romania, Slovenia, Croatia, Serbia, and the Former Yugoslavian Republic of Macedonia. Financial terms were not disclosed.
Alfacell and US Pharmacia
In July 2007, Alfacell and US Pharmacia announced that Alfacell has entered into a distribution agreement with USP Pharma Spolka Z.O.O. (USP Pharma), an affiliate of US Pharmacia, for the commercialization of ONCONASE (ranpirnase) in Eastern Europe. Under the distribution agreement, Alfacell has granted USP Pharma exclusive rights for the marketing, sales and distribution of ONCONASE in...See full deal structure in Biomedtracker
Partners: GENESIS Pharma US Pharmacia MegaPharm Ltd. BL&H Co., Ltd.
Pink Sheet Alfacell Onconase NDA rolls on track
Pink Sheet Financings In Brief: Alfacell
Additional information available to subscribers only: